Carbon-ion radiotherapy for locally recurrent rectal cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1404 Rectum

Makoto Shinoto, Shigeru Yamada, Masahiko Okamoto, Yoshiyuki Shioyama, Tatsuya Ohno, Takashi Nakano, Kenji Nemoto, Yuka Isozaki, Shohei Kawashiro, Hiroshi Tsuji, Tadashi Kamada

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: We investigated the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for locally recurrent rectal cancer (LRRC). Patients and methods: Data from patients with LRRC treated with C-ion RT from November 2003 to December 2014 at three institutions were retrospectively analyzed. The endpoints of this clinical trial were overall survival (OS), local control (LC), and acute/late toxicity. Results: A total of 224 patients' data were collected. The prescribed dose was 70.4 Gy (relative biological effectiveness [RBE]-weighted absorbed dose) or 73.6 Gy (RBE) in 16 fractions. The median follow-up period from the initiation of C-ion RT was 62 months (range 6–169 months). The OS rates were 73% (95% confidence interval [CI], 67%–79%) at 3 years and 51% (95%CI 44%–58%) at 5 years. The LC rates were 93% (95%CI 88%–96%) at 3 years, and 88% (95%CI 82%–93%) at 5 years. Grade 3 acute toxicity was observed in three patients: gastrointestinal toxicity (n = 1) and pelvic infection (n = 2). Grade 3 late toxicity was observed in 12 patients: skin reaction (n = 2), gastrointestinal toxicity (n = 2), neuropathy (n = 1), and pelvic infection (n = 7). There was no grade 4 or 5 acute or late toxicity. Conclusions: This first multi-institutional analysis of C-ion RT for LRRC indicated relatively favorable outcomes with limited toxicities.

Original languageEnglish
Pages (from-to)236-240
Number of pages5
JournalRadiotherapy and Oncology
Volume132
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Heavy Ion Radiotherapy
Radiation Oncology
Rectal Neoplasms
Rectum
Japan
Carbon
Ions
Pelvic Infection
Relative Biological Effectiveness
Confidence Intervals
Survival Rate
Clinical Trials
Safety
Skin
Survival

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Carbon-ion radiotherapy for locally recurrent rectal cancer : Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1404 Rectum. / Shinoto, Makoto; Yamada, Shigeru; Okamoto, Masahiko; Shioyama, Yoshiyuki; Ohno, Tatsuya; Nakano, Takashi; Nemoto, Kenji; Isozaki, Yuka; Kawashiro, Shohei; Tsuji, Hiroshi; Kamada, Tadashi.

In: Radiotherapy and Oncology, Vol. 132, 01.03.2019, p. 236-240.

Research output: Contribution to journalArticle

Shinoto, M, Yamada, S, Okamoto, M, Shioyama, Y, Ohno, T, Nakano, T, Nemoto, K, Isozaki, Y, Kawashiro, S, Tsuji, H & Kamada, T 2019, 'Carbon-ion radiotherapy for locally recurrent rectal cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1404 Rectum', Radiotherapy and Oncology, vol. 132, pp. 236-240. https://doi.org/10.1016/j.radonc.2018.10.007
Shinoto, Makoto ; Yamada, Shigeru ; Okamoto, Masahiko ; Shioyama, Yoshiyuki ; Ohno, Tatsuya ; Nakano, Takashi ; Nemoto, Kenji ; Isozaki, Yuka ; Kawashiro, Shohei ; Tsuji, Hiroshi ; Kamada, Tadashi. / Carbon-ion radiotherapy for locally recurrent rectal cancer : Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1404 Rectum. In: Radiotherapy and Oncology. 2019 ; Vol. 132. pp. 236-240.
@article{4e2492bb71ef44729e4aa3f9bd90da35,
title = "Carbon-ion radiotherapy for locally recurrent rectal cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1404 Rectum",
abstract = "Purpose: We investigated the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for locally recurrent rectal cancer (LRRC). Patients and methods: Data from patients with LRRC treated with C-ion RT from November 2003 to December 2014 at three institutions were retrospectively analyzed. The endpoints of this clinical trial were overall survival (OS), local control (LC), and acute/late toxicity. Results: A total of 224 patients' data were collected. The prescribed dose was 70.4 Gy (relative biological effectiveness [RBE]-weighted absorbed dose) or 73.6 Gy (RBE) in 16 fractions. The median follow-up period from the initiation of C-ion RT was 62 months (range 6–169 months). The OS rates were 73{\%} (95{\%} confidence interval [CI], 67{\%}–79{\%}) at 3 years and 51{\%} (95{\%}CI 44{\%}–58{\%}) at 5 years. The LC rates were 93{\%} (95{\%}CI 88{\%}–96{\%}) at 3 years, and 88{\%} (95{\%}CI 82{\%}–93{\%}) at 5 years. Grade 3 acute toxicity was observed in three patients: gastrointestinal toxicity (n = 1) and pelvic infection (n = 2). Grade 3 late toxicity was observed in 12 patients: skin reaction (n = 2), gastrointestinal toxicity (n = 2), neuropathy (n = 1), and pelvic infection (n = 7). There was no grade 4 or 5 acute or late toxicity. Conclusions: This first multi-institutional analysis of C-ion RT for LRRC indicated relatively favorable outcomes with limited toxicities.",
author = "Makoto Shinoto and Shigeru Yamada and Masahiko Okamoto and Yoshiyuki Shioyama and Tatsuya Ohno and Takashi Nakano and Kenji Nemoto and Yuka Isozaki and Shohei Kawashiro and Hiroshi Tsuji and Tadashi Kamada",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.radonc.2018.10.007",
language = "English",
volume = "132",
pages = "236--240",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Carbon-ion radiotherapy for locally recurrent rectal cancer

T2 - Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1404 Rectum

AU - Shinoto, Makoto

AU - Yamada, Shigeru

AU - Okamoto, Masahiko

AU - Shioyama, Yoshiyuki

AU - Ohno, Tatsuya

AU - Nakano, Takashi

AU - Nemoto, Kenji

AU - Isozaki, Yuka

AU - Kawashiro, Shohei

AU - Tsuji, Hiroshi

AU - Kamada, Tadashi

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Purpose: We investigated the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for locally recurrent rectal cancer (LRRC). Patients and methods: Data from patients with LRRC treated with C-ion RT from November 2003 to December 2014 at three institutions were retrospectively analyzed. The endpoints of this clinical trial were overall survival (OS), local control (LC), and acute/late toxicity. Results: A total of 224 patients' data were collected. The prescribed dose was 70.4 Gy (relative biological effectiveness [RBE]-weighted absorbed dose) or 73.6 Gy (RBE) in 16 fractions. The median follow-up period from the initiation of C-ion RT was 62 months (range 6–169 months). The OS rates were 73% (95% confidence interval [CI], 67%–79%) at 3 years and 51% (95%CI 44%–58%) at 5 years. The LC rates were 93% (95%CI 88%–96%) at 3 years, and 88% (95%CI 82%–93%) at 5 years. Grade 3 acute toxicity was observed in three patients: gastrointestinal toxicity (n = 1) and pelvic infection (n = 2). Grade 3 late toxicity was observed in 12 patients: skin reaction (n = 2), gastrointestinal toxicity (n = 2), neuropathy (n = 1), and pelvic infection (n = 7). There was no grade 4 or 5 acute or late toxicity. Conclusions: This first multi-institutional analysis of C-ion RT for LRRC indicated relatively favorable outcomes with limited toxicities.

AB - Purpose: We investigated the efficacy and safety of carbon-ion radiotherapy (C-ion RT) for locally recurrent rectal cancer (LRRC). Patients and methods: Data from patients with LRRC treated with C-ion RT from November 2003 to December 2014 at three institutions were retrospectively analyzed. The endpoints of this clinical trial were overall survival (OS), local control (LC), and acute/late toxicity. Results: A total of 224 patients' data were collected. The prescribed dose was 70.4 Gy (relative biological effectiveness [RBE]-weighted absorbed dose) or 73.6 Gy (RBE) in 16 fractions. The median follow-up period from the initiation of C-ion RT was 62 months (range 6–169 months). The OS rates were 73% (95% confidence interval [CI], 67%–79%) at 3 years and 51% (95%CI 44%–58%) at 5 years. The LC rates were 93% (95%CI 88%–96%) at 3 years, and 88% (95%CI 82%–93%) at 5 years. Grade 3 acute toxicity was observed in three patients: gastrointestinal toxicity (n = 1) and pelvic infection (n = 2). Grade 3 late toxicity was observed in 12 patients: skin reaction (n = 2), gastrointestinal toxicity (n = 2), neuropathy (n = 1), and pelvic infection (n = 7). There was no grade 4 or 5 acute or late toxicity. Conclusions: This first multi-institutional analysis of C-ion RT for LRRC indicated relatively favorable outcomes with limited toxicities.

UR - http://www.scopus.com/inward/record.url?scp=85055117036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055117036&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2018.10.007

DO - 10.1016/j.radonc.2018.10.007

M3 - Article

C2 - 30360998

AN - SCOPUS:85055117036

VL - 132

SP - 236

EP - 240

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

ER -